Balanced news tone
News Sentiment
BOLT sentiment intelligence
Bolt Biotherapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
48
Balanced news tone
40 relevant articles
Price is moving more forcefully than the current news tone suggests.
74/100 classification confidence.
directly relevant articles
high-authority source matches
+16.9% over one week, +10.8% over four weeks, trend inactive, and below fair value.
BOLT Forecast — Price Target — Prediction for 2027
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Earnings
74/100 classification
One-week reaction
16.9%
Price confirming higher
Trend fit
Trend inactive
10.8% over four weeks
Fair value
-63.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
23
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
standard-journal.com
Direct company coverage
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot
Bolt Biotherapeutics Inc. reported a Q1 loss of $7.2 million, or $4.31 per share, with unspecified revenue for the period. The company's shares closed at $5.96 on Tuesday, remaining below their previous year's trading price of $7.50. This financial snapshot was generated using da
- Tone
- Negative 14/100
- Event
- Earnings
- Published
- 13 May 2026 01:09
- Source
- standard-journal.com
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Business Wire
Direct company coverage
Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Feb 2026 08:00
- Source
- Business Wire
PR Newswire
Direct company coverage
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 03 Sep 2024 07:00
- Source
- PR Newswire
MarketBeat
Direct company coverage
Bolt Biotherapeutics (BOLT) Stock Forecast and Price Target 2026 $BOLT
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 11 May 2024 13:36
- Source
- MarketBeat
Zacks Investment Research
Direct company coverage
Should I buy Bolt Biotherapeutics (BOLT)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Aug 2016 10:03
- Source
- Zacks Investment Research
MarketBeat
Direct company coverage
Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $BOLT
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Aug 2016 09:32
- Source
- MarketBeat